Compare CVS Health Corp (CVS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Sana Biotechnology Inc — how do they compare? CVS Health Corp trades at $95.36 (market cap $121.14B), while Sana Biotechnology Inc trades at $3.66 (market cap $1.13B). The key difference: CVS Health Corp is far larger — about 107.2× Sana Biotechnology Inc's market cap, and CVS Health Corp pays a 2.81% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| CVS | SANA | |
|---|---|---|
Market Cap | $121.14B | $1.13B |
Sector | Health | Health |
52-Week High | $110.60 | $5.92 |
52-Week Low | $66.73 | $2.68 |
Enterprise Value | $183.49B | $1.05B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.99, up 1.59% today, with a bearish technical signal but strong fundamentals including a low P/S of 0.29 and three consecutive quarterly EPS beats. Revenue grew to $402.07B in 2025, though net margin compressed to 0.43%. Recent news highlights Q2 2026 earnings exceeding expectations and raised guidance, driven by Aetna's recovery and retail strength.
The outlook is mixed: analyst consensus is bullish with an $116.09 price target (22% upside), but risks include margin pressure from PBM changes in 2027 and rising debt levels. Near-term catalysts include the Q3 2026 earnings report, while long-term growth depends on integrated healthcare execution.
SANA Biotechnology trades at $3.77, down 0.53% on the day, with strong analyst support showing 82% buy ratings. The stock exhibits bullish technical signals despite negative profitability metrics, including a -152.87% ROE. Recent clinical data presentations at major medical conferences highlight progress in engineered cell therapies for diabetes treatment.
While analyst consensus remains positive with a $9.50 price target, the company faces significant financial challenges with substantial cash burn and negative earnings. Investment opportunity lies in clinical pipeline success, but risks include ongoing losses and shareholder litigation concerns that could impact near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
